XellSmart Secures Fourth Consecutive FDA and NMPA Approval for iPSC Cell Therapy Targeting Rare Neurodegenerative Disease MSA-P
Key Insights
XellSmart (search) received its fourth consecutive US FDA and China NMPA clearance for Phase I/II clinical trials of an iPSC-derived cell therapy targeting Multiple System Atrophy-Parkinsonian Type (search) (MSA-P (search)), a rare and fatal neurodegenerative disease.
The company now has nine approved INDs for iPSC-derived cell therapies targeting major CNS diseases including Parkinson's disease (search), spinal cord injury (search), ALS (search), and MSA-P (search), demonstrating significant regulatory confidence.
Clinical data from XellSmart (search)'s Parkinson's disease (search) trials showed promising safety and efficacy signals, with patients experiencing extended "ON state" periods and improved motor function scores.
XellSmart Pharmaceutical Co., Ltd. (search) announced in February 2026 that it secured its fourth consecutive US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its independently developed iPSC-derived cell therapy targeting Multiple System Atrophy-Parkinsonian Type (search) (MSA-P (search)). This milestone adds to the company's previous three consecutive FDA-NMPA registrational trial clearances for universal iPSC-derived cell therapies targeting Parkinson's Disease (search), Spinal Cord Injury (search), and Amyotrophic Lateral Sclerosis (search).
Addressing Critical Unmet Medical Need
MSA-P (search) represents a significant therapeutic challenge, recognized by the World Health Organization as a rare and fatal neurodegenerative disease with substantial unmet medical needs. The condition primarily presents with progressive Parkinsonian syndrome, including bradykinesia, rigidity, and gait disorders, accompanied by severe autonomic nerve dysfunction such as orthostatic hypotension and urinary incontinence.
The disease is triggered by abnormal aggregation of α-synuclein (search) in oligodendrocytes, causing extensive loss of neuronal function and rapid progression. Patients face a particularly grim prognosis, with median survival after diagnosis of merely 6 to 10 years.
Current treatment options remain severely limited. Standard clinical treatment includes dopaminergic drugs for Parkinson's-like motor symptoms, such as levodopa/carbidopa, combined with other dopaminergic therapies when necessary. However, the overall response is often inferior to that observed in Parkinson's disease (search), with limited efficacy. Non-pharmacological treatments focus on managing autonomic dysfunction, rehabilitation training, fall prevention, and nutritional support to maintain patients' physical function and quality of life.
Critically, no approved therapies exist anywhere in the world that can effectively slow or reverse MSA-P (search) disease progression.
Expanding iPSC-Derived Cell Therapy Pipeline
XellSmart (search)'s approach employs off-the-shelf, allogeneic, universal, iPSC-derived, subtype-specific neuron progenitor cell therapy. The company's innovative mechanism aims to regenerate dopamine secretion and promote circuit and brain environment repair, exploring a novel treatment approach for MSA-P (search) with the potential to deliver new therapeutic options to patients worldwide.
The company now operates nine cleared INDs from US FDA and China NMPA for Phase I/II registrational clinical trials. These trials employ clinical-grade, allogeneic, universal, off-the-shelf, iPSC-derived cell therapeutic products targeting major CNS diseases including Parkinson's Disease (search), Spinal Cord Injury (search), ALS (search), and MSA-P (search).
Key ongoing trials include China Phase I/II and US Phase I registrational clinical trials targeting primary Parkinson's disease (search), led by Beijing Tiantan Hospital (search), a prestigious National Center for Neurological Disorders. The company is also conducting China's first randomized, double-blind, controlled clinical trial of universal cell therapy targeting early-onset Parkinson's disease, led by Huashan Hospital Fudan University.
Promising Clinical Data from Parkinson's Disease Trials
XellSmart (search)'s MSA-P (search) program builds on encouraging clinical data from its Parkinson's disease (search) trials conducted at National Centers for Neurological Disorders. The trials enrolled more than a dozen patients with moderate to severe PD, demonstrating several key outcomes after cell transplantation treatment.
No unexpected safety signals have been observed to date. Patients showed positive trends for efficacy indicators including 'ON/OFF state' and MDS-UPDRS motor scores. The average "ON state" was extended by several hours, coupled with significant relief in "OFF state," contrasting with pre-treatment difficulty in movement and significant limitations after medication failure. The time for daily free movement and maintaining relatively high quality of life increased significantly.
Brain PET examination suggested potential survival and function from newly generated dopaminergic cells in the putamen region, indicating a trend of long-term survival and maturation of engrafted neurons.
Strong Financial and Regulatory Support
Since its 2021 inception, XellSmart (search) has secured five consecutive years of market-driven funding from renowned venture capital firms including FreeS Fund, Qiming Venture Partners, LAV, Sequoia Capital China (Hongshan), and 3SBIO. These proceeds support the company's key pipeline products advancing into pivotal validation clinical stages and ensure future commercial roll-out through strengthened large-scale, standardized production capacity and quality management systems for off-the-shelf iPSC-derived cell products.
The China and US Phase I/II registrational clinical trials targeting MSA-P (search) are projected to commence in 2026, representing another significant milestone in XellSmart (search)'s comprehensive approach to addressing underserved neurodegenerative diseases through cutting-edge iPSC-derived cell therapy innovation.